Results 71 to 80 of about 628,285 (376)

Characteristics of the Kelch domain containing (KLHDC) subfamily and relationships with diseases

FEBS Letters, Volume 599, Issue 8, Page 1094-1112, April 2025.
The Kelch protein superfamily includes 63 members, with the KLHDC subfamily having 10 proteins. While their functions are not fully understood, recent advances in KLHDC2's structure and role in protein degradation have highlighted its potential for drug development, especially in PROTAC therapies.
Courtney Pilcher, Paula Armina V. Buco, Jia Q. Truong, Paul A. Ramsland, Monique F. Smeets, Carl R. Walkley, Jessica K. Holien   +6 more
wiley   +1 more source

Investigating the mechanism of Xian-ling-lian-xia-fang for inhibiting vasculogenic mimicry in triple negative breast cancer via blocking VEGF/MMPs pathway

Chinese Medicine, 2022
Background Xian-ling-lian-xia-fang (XLLXF), a Chinese medicine decoction, is widely used in the treatment of triple negative breast cancer (TNBC). However, the underlying mechanism of XLLXF in TNBC treatment has not been totally elucidated. Methods Here,
Feifei Li, Youyang Shi, Yang Zhang, Xiaojuan Yang, Yi Wang, Kexin Jiang, Ciyi Hua, Chunyu Wu, Chenping Sun, Yuenong Qin, Sheng Liu   +10 more
doaj   +1 more source

The apo LETM1 F‐EF‐hand adopts a closed conformation that underlies a multi‐modal sensory role in mitochondria

FEBS Letters, Volume 599, Issue 7, Page 971-988, April 2025.
We present the first solution structure of the Ca2+‐depleted LETM1 F‐EF‐hand through a D676A/N678A Ca2+ binding‐deficient mutant, revealing a closed hydrophobic cleft caused by a unique F1‐helix pivot. The apo LETM1 F‐EF‐hand exhibits regiospecific hot and cold unfolding, sensitivity to physiological pH changes and potential for promiscuous heterotypic
Qi‐Tong Lin, Danielle M. Colussi, Peter B. Stathopulos   +2 more
wiley   +1 more source

Network Pharmacology-Guided Development of a Novel Integrative Regimen to Prevent Acute Graft-vs.-Host Disease

Frontiers in Pharmacology, 2018
Lapses in the graft-vs.-host disease (GVHD) prophylaxis and side effects of current standard care following allogeneic hematopoietic stem cell transplantation (allo-HSCT) call for novel regimens.
Ming Lyu, Ming Lyu, Zhengcan Zhou, Xiaoming Wang, Xiaoming Wang, Hong Lv, Hong Lv, Mei Wang, Guixiang Pan, Guixiang Pan, Yuefei Wang, Yuefei Wang, Guanwei Fan, Xiumei Gao, Yuxin Feng, Yuxin Feng, Yan Zhu, Yan Zhu   +17 more
doaj   +1 more source

Prediction of the mechanism for the combination of diallyl trisulfide and cisplatin against gastric cancer: a network pharmacology study and pharmacological evaluation

Frontiers in Pharmacology, 2023
Background: In this research, we aimed to explore the efficacy of diallyl trisulfide (DATS) combined with cisplatin (DDP) for gastric cancer treatment and its underlying mechanism based on network pharmacology.Methods: First, the pharmacological ...
Huaiyou Lv, Huaiyou Lv, Huaiyou Lv, Xiumei Jia, Huatian Yang, Xiaosong Zhu, Xiaosong Zhu, Zhongxi Zhao, Xiaoyan Jiang, Xiaoyan Jiang   +9 more
doaj   +1 more source

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands [PDF]

, 2015
The IUPHAR/BPS Guide to PHARMACOLOGY (GtoPdb, http://www.guidetopharmacology.org) provides expert-curated molecular interactions between successful and potential drugs and their targets in the human genome.
Adam J. Pawson, Anthony P. Davenport, Christopher Southan, Doriano Fabbro, Elena Faccenda, Helen E. Benson, Jamie A. Davies, Joanna L. Sharman, John A. Peters, John C. McGrath, Knapp, Li, Mathias, Michael Spedding, O. Peter Buneman, Stephen P. H. Alexander, Tough, William A. Catterall   +17 more
core   +5 more sources

Immunoregulatory mechanisms of the arachidonic acid pathway in cancer

FEBS Letters, Volume 599, Issue 7, Page 927-951, April 2025.
The central role of the arachidonic acid (AA) pathway in anticancer immunity. Enzymes and metabolites of the AA pathway can play both immunosuppressive and immunostimulatory roles in the tumor microenvironment. Therefore, their tailored targeting could be beneficial as a standalone therapy or in combination with current cancer immunotherapy.
Maria Tredicine, Matteo Mucci, Antonio Recchiuti, Domenico Mattoscio   +3 more
wiley   +1 more source

Mathematical model of a telomerase transcriptional regulatory network developed by cell-based screening: analysis of inhibitor effects and telomerase expression mechanisms [PDF]

, 2014
Cancer cells depend on transcription of telomerase reverse transcriptase (TERT). Many transcription factors affect TERT, though regulation occurs in context of a broader network. Network effects on telomerase regulation have not been investigated, though
A Agrawal, A De Cian, A Goltsov, A Graudenzi, A Schonthal, A Subramanian, A Tapias, A Tapias, A von Kriegsheim, A Wuensche, AE Bilsland, AE Bilsland, AE Bilsland, AE Bilsland, Alan E. Bilsland, B Tang, C Jiang, C Lawless, C Torres-Sosa, CJ Anderson, Claire J. Cairney, D Hanahan, D Machado, D Xu, DE Nelson, DG Johnson, DH Crouch, DJ Billingsley, DL Crowe, DR White, E Yang, EJ Black, F Gizard, FW Huang, G Niu, G Wrobel, H Yuan, J Cho, J Grefenstette, J Won, J Zhao, JN Davis, Jon Roffey, JS Ho, K Cho, K Jiang, K Lafferty-Whyte, K Lafferty-Whyte, K Lafferty-Whyte, K Ookawa, K Thalmeier, K Willadsen, Katrina Stevenson, KI Zeller, KJ Wu, KM Ryan, L Chen, L Durant, L Konnikova, LA Bell, LC Freeman, LE Sivak, LG Wooten-Blanks, LI Chen, M Choi, M Daniel, M Kohl, M Nicolas, M Takakura, N Arkus, N Benson, N Kley, OE Akman, OW Rokhlin, P Angel, PJ Killela, PM Neilsen, Q Wang, R Duan, R Schlatter, R Wilds, RT Sitaram, S Horn, S Hossain, S Huang, S Kauffman, S Kyo, S Mangan, S Oh, Satoru Miyano, SM Mac, SP Hsu, Stacey Hoare, SY Lin, T Kanaya, T Maki-Marttunen, T Sengupta, TG Oliver, TH Kim, U Moehren, V Anest, V Batagelj, VJ Gnanapragasam, VK Mootha, W. Nicol Keith, WB Lee, X Chen, Y Xiao, Y Xing, Y Yao, Yu Liu   +110 more
core   +6 more sources

Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain [PDF]

, 2012
The development of clinica lpractice recommendations or guidelines for the clinical use of biomarkers is an issue of great importance withr regard to adverse drug reactions.The poten-tial of pharmacogenomicbiomarkers has been extensively investigated in
Abad Santos, Francisco, Aldea, Ana, Alonso-Navarro, Hortensia, Bernal, María Luisa, Borobia, Alberto M., Borràs, Emma, Carballo, Miguel, Carvajal, Alfonso, García-Agúndez, José Augusto, García-Martín, Elena, García-Muñiz, José D., Gervasini, Guillermo, Jiménez-Jiménez, Félix Javier, Lucena, María Isabel, Martínez, Carmen, Sacristán, José A., Salado, Inés, Sinués, Blanca, Vicente, Jorge   +18 more
core   +4 more sources

Identification of novel small molecule inhibitors of ETS transcription factors

FEBS Letters, EarlyView.
ETS transcription factors play an essential role in tumourigenesis and are indispensable for sprouting angiogenesis, a hallmark of cancer, which fuels tumour expansion and dissemination. Thus, targeting ETS transcription factor function could represent an effective, multifaceted strategy to block tumour growth. The evolutionarily conserved E‐Twenty‐Six
Shaima Abdalla, Zary Forghany, Jin Ma, Johan G. Hollander, Ruta Nachane, Karoly Szuhai, Pancras C. W. Hogendoorn, Peter ten Dijke, Dipen Shah, David A. Baker   +9 more
wiley   +1 more source